Carl Zeiss Meditec
Open enrollment across a mixed-phase pipeline
According to ClinicalTrials.gov-derived indexes, Carl Zeiss Meditec sits in the top decile of US sponsors by registered trial count (#801 of 15,742 sponsors by registered trial count).
Carl Zeiss Meditec: 18 sponsored US clinical trials, 2 recruiting.
Carl Zeiss Meditec sponsors 18 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting, and 15 completed. 1 of these trials are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Cataract, with 2 trials.
Top-decile sponsor footprint
Carl Zeiss Meditec ranks in the top decile of sponsors by registered trial count (#801 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
15 of 16 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (93.8%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
18 total, page 1 of 1
Evaluation of Cataract Surgery Outcomes in Patients With Prior Laser Vision Correction Implanted With the CT LUCIA Lens
NCT07084545
Evaluation of a Monofocal Intraocular Lens
NCT06428955
AT ELANA 841P Posterior Chamber Intraocular Lens for Correction of Aphakia Following Cataract Removal
NCT06264232
A Prospective Multicenter Study To Assess The Clinical Outcomes Of Current Phacoemulsification Approach To Cataract Extraction Versus The Micor System Device
NCT05729477
Post-approval Study of New Enrolment Patients Undergoing Bilateral Treatment With the VisuMax SMILE Procedure
NCT05740293
Assessment of Low Energy Lens Fragmentation Cataract Extraction in Patients Undergoing Cataract Surgery
NCT04747834
Repeatability and Reproducibility of the IOLMaster 700 Vers 1.70 and Agreement With IOLMaster 700 Vers. 1.50 and Pentacam
NCT03518775
Correction of Myopia Wtih or Without Astigmatism Using the VisuMax™ Femtosecond Laser
NCT02430428
Use of the VisuMax™ Femtosecond Laser
NCT01638390
Repeatability and Reproducibility of Cirrus HD-OCT Macular Retinal Pigment Epithelium Elevation
NCT01890174
Cirrus HD-OCT Measurement of Area of Increased Light Penetration Under the Retinal Pigment Epithelium (RPE)
NCT01272076
Macular Ganglion Cell Analysis (GCA) of the Cirrus HD-OCT in Glaucoma
NCT01272102
Repeatability and Reproducibility of Cirrus HD-OCT Measurements of Illumination Areas Under the Retinal Pigment Epithelium
NCT01890187
Measurement and Analysis of Macular Retinal Pigment Epithelium (RPE) Elevations With Cirrus HD-OCT vs. Color Fundus Photography
NCT01272063
Screening Aid to Identify Corneas That May Have Pathologies or Other Conditions
NCT00396188
Study of the MEL 80 Excimer Laser Using LASIK in the Treatment of Mixed Astigmatism
NCT00761826
Study of the MEL 80 Excimer Laser Using LASIK in the Treatment of Moderate to High Myopia
NCT00762541
Safety and Effectiveness Study of the MEL 80 Excimer Laser Using LASIK in the Treatment of Hyperopia
NCT00762281
What is open in the Carl Zeiss Meditec pipeline
2 recruiting of 18 indexed (11% open); 15 completed (83%).
Phase mix: 1 late (III/IV) vs 1 early (I/II) (balanced across stages).
Top condition: Cataract (2 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Carl Zeiss Meditec: open-pipeline peers nationwide
Peers matched on 18 registered trials and 11% open enrollment, not the therapeutic-area sidebar.
Carl Zeiss Meditec sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 18 trials (± recruiting share)
- ADC Therapeutics S.A. · 18 trials · 11% recruiting
- Akros Pharma · 18 trials · 0% recruiting
- AO Clinical Investigation and Publishing Documentation · 18 trials · 0% recruiting
- AO Innovation Translation Center · 18 trials · 33% recruiting
Sponsors near 11% open enrollment (± trial volume)
- Adrian Vella · 11% recruiting · 9 trials
- AIDS Malignancy Consortium · 11% recruiting · 45 trials
- Amylyx Pharmaceuticals · 11% recruiting · 9 trials
- Aprea Therapeutics · 11% recruiting · 9 trials
Related
What to do with this Carl Zeiss Meditec page
18 registered trials is a research-attention snapshot, not an endorsement of Carl Zeiss Meditec or any single study.
- 2 of Carl Zeiss Meditec's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Cataract is the condition Carl Zeiss Meditec studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Cataract trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Carl Zeiss Meditec pipeline card: 18 registered trials from official public datasets.Report a data error.